Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OT-101 + Pembrolizumab in Refractory Malignant Pleural Mesothelioma
NCT05425576Phase 2Not yet recruiting
- Sponsor
- Oncotelic Therapeutics, Inc.
- Start
- Jun 2025
- Primary completion
- Dec 2028
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of trabedersen in malignant pleural mesothelioma (MPM), sponsored by Oncotelic Therapeutics, Inc.. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
trabedersen
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT05425576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05425576.